You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 09/23/2014

Company Name Symbol %Change
Myriad Genetics Bullish Moving Average Crossover Alert (MYGN)

Print Share

Dec 18, 2012 (Moving average crossovers via COMTEX) -- Myriad Genetics (NASDAQ:MYGN) shares have crossed bullishly above their 10-day moving average of $27.43 on a volume of 240K shares. This may provide swing traders with an opportunity for a long position, as such a crossover often suggests higher prices in the near term.In the past 52 weeks, Myriad Genetics share prices have been bracketed by a low of $17.51 and a high of $31.80 and are now at $27.55, 57% above that low price. The 200-day and 50-day moving averages have moved 0.16% higher and 0.17% lower over the past week, respectively.

Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.

There is potential upside of 14.5% for shares of Myriad Genetics based on a current price of $27.55 and an average consensus analyst price target of $31.55. Myriad Genetics shares should encounter resistance at the 50-day moving average (MA) of $28.12 and support at its 200-day MA of $25.80.


Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit today.

Copyright, Comtex News Network, Inc. 2012

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.